Initially approved for type 2 diabetes mellitus, SGLT2 inhibitors were subsequently found to reduce HF hospitalizations and cardiovascular death, prompting investigation into their use in patients with HF and chronic kidney disease. The gene discussed is SLC5A2; the disease is hydrops fetalis.